- Home
- OPFI vs BWAY Comparison
OPFI vs BWAY Comparison
Compare OPFI & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- BWAY
- Stock Information
- Founded
- OPFI 2009
- BWAY 2003
- Country
- OPFI United States
- BWAY Israel
- Employees
- OPFI N/A
- BWAY N/A
- Industry
- OPFI Finance: Consumer Services
- BWAY Medical/Dental Instruments
- Sector
- OPFI Finance
- BWAY Health Care
- Exchange
- OPFI Nasdaq
- BWAY Nasdaq
- Market Cap
- OPFI 382.4M
- BWAY 245.2M
- IPO Year
- OPFI N/A
- BWAY 2019
- Fundamental
- Price
- OPFI $11.67
- BWAY $12.20
- Analyst Decision
- OPFI Buy
- BWAY Strong Buy
- Analyst Count
- OPFI 2
- BWAY 2
- Target Price
- OPFI $11.75
- BWAY $14.25
- AVG Volume (30 Days)
- OPFI 1.3M
- BWAY 51.5K
- Earning Date
- OPFI 08-06-2025
- BWAY 08-05-2025
- Dividend Yield
- OPFI 8.35%
- BWAY N/A
- EPS Growth
- OPFI N/A
- BWAY N/A
- EPS
- OPFI N/A
- BWAY 0.08
- Revenue
- OPFI $305,566,000.00
- BWAY $43,457,000.00
- Revenue This Year
- OPFI $113.99
- BWAY $351.53
- Revenue Next Year
- OPFI $9.05
- BWAY $21.84
- P/E Ratio
- OPFI N/A
- BWAY $60.38
- Revenue Growth
- OPFI 31.46
- BWAY 26.86
- 52 Week Low
- OPFI $3.09
- BWAY $5.98
- 52 Week High
- OPFI $17.73
- BWAY $13.66
- Technical
- Relative Strength Index (RSI)
- OPFI 37.15
- BWAY 52.57
- Support Level
- OPFI $13.13
- BWAY $12.10
- Resistance Level
- OPFI $14.97
- BWAY $13.66
- Average True Range (ATR)
- OPFI 0.77
- BWAY 0.47
- MACD
- OPFI -0.31
- BWAY -0.16
- Stochastic Oscillator
- OPFI 2.41
- BWAY 10.46
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.